Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 43, Issue 10, 2002, Pages 1911-1920

  Pinheiro, J P Vieira ^a   Lanvers, C ^a   Wurthwein G ^a   Beier, R ^b   Palma, J Casimiro Da ^c   Von Stackelberg, A ^c   Boos, J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ALL; Asparaginase; Children; Drug monitoring; Pharmacokinetics

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; TIME; ACUTE LYMPHOCYTIC LEUKEMIA; BLOOD; INFANT; PRESCHOOL CHILD; REPRODUCIBILITY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; DRUG MONITORING; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LYMPHOMA, NON-HODGKIN; MALE; POLYETHYLENE GLYCOLS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 0036786613     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000015853     Document Type: Article

References (50)

1. Ettinger, L.J., Ettinger, A.G., Avramis, V.I. and Gaynon, P.S. (1997) "Acute lymphoblastic leukaemia: a guide to asparaginase and pegaspargase therapy", BioDrugs 7(1), 30-39.
2. Haley, E.E., Fischer, G.A. and Welch, A.D. (1961) "The requirement for L-asparagine of mouse leukemia cells L5178Y in culture", Cancer Research 21, 532-536.
3. Prager, M.D. and Bachynsky, N. (1968) "Asparagine synthetase in normal and malignant tissues: correlation with tumor sensitivity to asparaginase", Archives of Biochemistry and Biophysics 127(1), 645-654.
4. Cooney, D. and Handschuhmacher, R. (1970) "L-asparaginase and L-asparagine metabolism", Annual Review of Pharmacology 10, 421-440.
5. Capizzi, R.L. (1993) "Asparaginase revisited", Leukemia and Lymphoma 10, 147-150.
6. Müller, H.J. and Boos, J. (1998) "Use of L-asparaginase in childhood ALL", Critical Reviews in Oncology and Hematology 28(2), 97-113.
7. Evans, W.E., Tsiatis, A., Rivera, G., Murphy, S.B., Dahl, G.V., Denison, M., Crom, W.R., Barker, L.F. and Mauer, A.M. (1982) "Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma", Cancer 49, 1378-1383.
8. Oettgen, H.F., Stephenson, P.A., Schwartz, M.K., Leeper, R.D., Tallal, L., Tan, C.C., Clarkson, B.D., Golbey, R.B., Krakoff, I.H., Karnofsky, D.A., Murphy, M.L. and Burchenal, J.H., (1970) "Toxicity of E. coli L-asparaginase in man", Cancer 25, 253-278.
9. Ohnuma, T., Holland, J.F. and Meyer, P. (1972) "Erwinia carotorova asparaginase in patients with prior anaphylaxis to asparaginase from E. coli", Cancer 30, 376-381.
10. Billett, A.L., Carls, A., Gelber, R.D. and Sallan, S.E. (1992) "Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase", Cancer 70, 201-206.
11. Kamisaki, Y., Wada, H., Yagura, T., Matsushima, A. and Inada, Y. (1981) "Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol", Journal of Pharmacology and Experimental Therapeutics 216, 410-414.
12. Patel, S.S. and Benfield, P. (1996) "Pegaspargase (polyethylene glycol-L-asparaginase)", Clinical Immunotherapeutics 5(6), 492-496.
13. Asselin, B.L., Whitin, J.C., Coppola, D.J., Rupp, I.P., Sallan, S.E. and Cohen, H.J. (1993) "Comparative pharmacokinetic studies of three asparaginase preparations", Journal of Clinical Oncology 11, 1780-1786.
14. Berg, S.L., Balis, F.M., McCully, C.L., Godwin, K.S. and Poplack, D.G. (1993) "Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey", Cancer Chemotherapy and Pharmacology 32, 310-314.
15. Ho, D.H., Brown, S., Yen, A., Holmes, R., Keating, M., Abuchowski, A., Newman, R.A. and Krakoff, I.A. (1986) "Clinical pharmacology of polyethylene glycol-L-asparaginase", Drug Metabolism and Disposition 14, 349-352.
16. Boos, J., Werber, G., Ahlke, E., Schulze-Westhoff, P., Nowak-Göttl, U., Würthwein, G., Verspohl, E.J., Ritter, J. and Jürgens, H. (1996) "Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations", European Journal of Cancer 32A(9), 1544-1550.
17. Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.D., Henze, G., Gadner, H., Odenwald, E. and Riehm, H. (2000) "Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995", Leukemia 14, 2205-2222.
18. Schrappe, M., Reiter, A., Ludwig, W.D., Harbott, J., Zimmermann, M., Hiddemann, W., Niemeyer, C., Henze, G., Feldges, A., Zintl, F., Kornhuber, B., Ritter, J., Welte, K., Gadner, H. and Riehm, H. (2000) "Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of the trial ALL-BFM 90", Blood 95(11), 3310-3322.
19. Riccardi, R., Holcenberg, J.S., Glaubinger, D.L., Wood, J.H. and Poplack, D.G. (1981) "L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans", Cancer Research 41, 4554-4558.
20. Boos, J. and Jürgens, H. (1996) "Pegaspargase (Polyethylene glycol-L-asparaginase), a viewpoint", Clinical Immunotherapeutic 5, 497.
21. Müller, H.J., Löning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., von Schütz, V., Henze, G., Casimiro da Palma, J., Ritter, J., Vieira Pinheiro, J.P., Winkelhorst, M. and Boos, J. (2000) "Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols", British Journal of Haematology 110(2), 379-384.
22. Vieira Pinheiro, J.P., Müller, H.J., Schwabe, D., Gunkel, M., Casimiro da Palma, J., Henze, G., von Schütz, V., Winkelhorst, M. and Boos, J. (2001) "Drug monitoring of low-dose PEG-asparaginase (Oncaspar™) in children with relapsed acute lymphoblastic leukaemia", British Journal of Haemotology 113, 115-119.
23. 2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols", Cancer Chemotherapy and Pharmacology 49, 149-154.
24. Lanvers, C., Vieira Pinheiro, J.P., Hempel, G., Wuerthwein, G. and Boos J. (2002). "Analytical validation of a microplate reader based method for the therapeutic drug monitoring of L-asparaginase in human serum", Analytical Biochemistry, accepted for publication.
25. Werber, G., Ahlke, E., Nowak-Göttl, U., Jürgens, H., Verspohl, E.J. and Boos, J. (1997) "Asparaginase activities in vitro are highly sensitive to different buffer conditions", In: Büchner, T., ed, Acute Leukemias VI: Prognostic Factors and Treatment Strategies (Springer, Berlin, Heidelberg), pp S512-S516.
26. Holle, L.M. (1997) "Pegaspargase: an alternative?", Annals of Pharmacotherapy 31(5), 616-624.
27. Keating, M.J., Holmes, R., Lerner, S. and Ho, D.H. (1993) "L-asparaginase and PEG asparaginase-past, present and future", Leukemia and Lymphoma 10, 153-157.
28. Ahlke, E., Nowak-Göttl, U., Schulze-Westhoff, P., Werber, G., Börste, H., Würthwein, G., Jürgens, H. and Boos, J. (1997) "Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia", British Journal of Haematology 96, 675-681.
29. Vieira Pinheiro, J.P., Ahlke, E., Nowak-Göttl, U., Hempel, G., Müller, H.J., Lümkemann, K., Schrappe, M., Rath, B., Fleischhack, G., Mann, G. and Boos, J. (1999) "Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols", British Journal of Haematology 104, 313-320.
30. Asselin, B., Gelber, R. and Sallan, S. (1993) "Relative toxicity of E. coli L-asparaginase (ASP) and PEGasparaginase (PEG) in newly diagnosed childhood acute lymphoblastic leukemia (ALL)", Medical and Pediatric Oncology 21, 556.
31. Ettinger, L.J., Asselin, B., Poplack, D.J. and Kurtzberg, J. (1993) "Toxicity profile of PEG-L-asparaginase in native-L-asparaginase hypersensitive and non-hypersensitive patients with acute lymphoblastic leukemia (ALL)", Medical and Pediatric Oncology 21, 556.
32. Ettinger, L.J. and Lerner, E.D. (1994) "A toxicity study of Oncaspar® (PEG-asparaginase) in children with acute lymphoblastic leukemia (ALL)", Medical and Pediatric Oncology 23(3), 278.
33. Graham, M.L., Asselin, B.L., Herndon, 2nd, J.E., Casey, J.R., Chaffee, S., Ciocci, G.H., Daeschner, C.W., Davis, A.R., Gold, S., Halperin, E.C., Laughlin, M.J., Martin, P.L., Olson, J.F. and Kurtzberg, J. (1998) "Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia", Bone Marrow Transplantation 21(9), 879-885.
34. Greffe, B., Lambert-Kerzner, A. and Eno, M. (1993) "Hypercoagulable/prethrombotic state associated with PEG-L-asparaginase in pediatric leukemic patients", Thrombosis and Haemostasis 69, 335.
35. and the Pediatric Oncology GroupKurtzberg, J., Asselin, B., Pollack, B., Bernstein, M. and Buchanan, G. (1993) "PEG-L-asparaginase (PEGasp) vs. native E. coli asparaginase (ASP) for reinduction of relapsed lymphoblastic leukemia (ALL): POG 8866 phase II trial", Proceedings of the American Society for Clinical Oncology 12, 325.
36. Kurtzberg, J., Asselin, B., Poplack, D., Grebanier, A., Chen, R., Franklin, A., Scudiery, D. and Fisherman, J. (1993) "Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy", Proceedings of the American Association for Cancer Research 34, 304.
37. Kurtzberg, J. (1994) "A new look at PEG-L-asparaginase and other asparaginases in hematological malignancies", Cancer Investigation 12(Suppl. 1), 59-60.
38. Vilmer, E., Suciu, S., Ferster, A., Bertrand, Y., Cave, H., Thyss, A., Benoit, Y., Dastugue, N., Fournier, M., Souillet, G., Manel, A.M., Robert, A., Nelken, B., Millot, F., Lutz, P., Rialland, X., Mechinaud, F., Boutard, P., Behar, C., Chantraine, J.M., Plouvier, E., Laureys, G., Brock, P., Uyttebroeck, A., Margueritte, G., Plantaz, D., Norton, L., Francotte, N., Gyselinck, J., Waterkeyn, C., Solbu, G., Philippe, N. and Otten, J. (2000) "Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report", Leukemia 14, 2257-2266.
39. Abshire, T.C., Pollock, B.H., Billett, A.L., Bradley, P. and Buchanan, G.R. (2000) "Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study", Blood 96(5), 1709-1715.
40. Ohnuma, T., Holland, J.F., Freeman, A. and Sinks, L.F. (1970) "Biochemical and pharmacological studies with asparaginase in man", Cancer Research 30, 2297-2305.
41. Gerrits, G.P., Trijbels, F.J., Monnens, L.A., Gabreëls, F.J., de Abreu, R.A., Theeuwes, A.G. and van Raay-Selten, B. (1989) "Reference values for amino acids in cerebrospinal fluid of children determined using ion-exchange chromatography with fluorimetric detection", Clinica Chimica Acta 182, 271-280.
42. Woo, M.H., Hak, L.J., Storm, M.C., Gajjar, A.J., Sandlund, J.T., Harrison, P.L., Wang, B., Pui, C.H. and Relling, M.V. (1999) "Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia", Journal of Clinical Oncology 17(5), 1568-1573.
43. Lepage, N., McDonald, N., Dallaire, L. and Lambert, M. (1997) "Age-specific distribution of plasma amino acid concentrations in a healthy pediatric population", Clinical Chemistry 43(12), 2397-2402.
44. Schwartz, M.K., Lash, E.D., Oettgen, H.F. and Tomao, F.A. (1970) "L-Asparaginase activity in plasma and other biological fluids", Cancer 25, 244-252.
45. Dibenedetto, S.P., Di Cataldo, A., Ragusa, R., Meli, C. and Lo Nigro, L. (1995) "Levels of L-asparaginase in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia", Journal of Clinical Oncology 13, 339-344.
46. Rizzari, C., Zucchetti, M., Conter, V., Diomede, L., Bruno, A., Gavazzi, L., Paganini, M., Sparano, P., Lo Nigro, L., Aricò, M., Milani, M. and D'Incalci, M. (2000) "L-Asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukaemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure", Annals of Oncology 11, 189-193.
47. Gentili, D., Conter, V., Rizzari, C., Tschuemperlin, B., Zucchetti, M., Orlandoni, D., D'Incalci, M. and Masera, G. (1996) "L-Asparagine depletion in plasma and cerebrospinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia-Asparaginase", Annals of Oncology 7, 725-730.
48. Appel, I.M., den Boer, M.L., Reniers, N.C.M. and Pieters, R. (2002). "Determinants of asparaginase resistance in childhood acute lymphoblastic leukaemia, first results of pharmacokinetic data on asparaginase response". Abstract Book of the 3rd Biennial Hannover Symposium on Childhood Leukemia. Abstract No. 44.
49. Killander, D., Dohlwitz, A., Engstedt, L., Franzen, S., Gahrton, G., Gullbring, B., Holm, G., Holmgren, A., Höglund, S., Killander, A., Lockner, D., Mellstedt, H., Moe, P.J., Palmblad, J., Reizenstein, P., Skårberg, K.O., Swedberg, B., Udén, A.M., Wadman, B., Wide, M. and Åhström, L. (1976) "Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia", Cancer 37, 220-228.
50. Woo, M.H., Hak, L.J., Storm, M.C., Sandlund, J.T., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Harrison, P.L., Wang, B., Evans, W.E., Pui, C.H. and Relling, M.V. (2000) "Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia", Journal of Clinical Oncology 18(7),